Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer

Oncogene volume 23, pages 7047–7052 (2004)Cite this article

A Corrigendum to this article was published on 16 December 2004

Abstract

Survivin and XIAP are members of inhibitors of apoptosis (IAPs) family. They are upregulated in various malignancies. Inactivation of these molecules has resulted in chemosensitization. The purpose of this study was to determine whether inhibition of survivin, XIAP, or both enhances radiotherapy in a lung cancer model. Transient transfection of H460 cells with antisense oligonucleotides (ASOs) against either molecule has specifically reduced their expression, by Western analysis. Results from 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide and clonogenic assays suggest that inhibition of survivin or XIAP greatly decreased cell survival following irradiation. A significantly increased number of apoptotic cells were detected when H460 cells were treated with either antisurvivin, anti-XIAP or both ASOs (P=0.03, 0.0003 and 0.01, respectively) plus irradiation. H460 xenografts that were treated with ASOs plus radiotherapy demonstrated growth delay beyond 15 days. Growth delay in the groups of combined treatment was greater than that in other groups. However, treatment with ASOs alone did not affect tumor growth delay in mice, but decreased the survival of H460 cells in culture. Antisense treatment did not cause any mortality or weight loss during the 32 days of study. These data suggest that inhibition of survivin or XIAP radiosensitizes H460 lung cancer cells by upregulating apoptosis and downregulating cell survival. Combination of radiotherapy and inhibition of survivin and XIAP through the antisense approach results in improved tumor control by radiotherapy in a mouse model of lung cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

Abbreviations

HUVEC:

human umbilical vein endothelial cells

VEGF:

vascular endothelial growth factor

IAP:

inhibitor of apoptosis

ASO:

antisense oligonucleotides

XIAP:

X-linked inhibitor of apoptosis protein

References

  • Adams RR, Carmena M and Earnshaw WC . (2001). Trends Cell Biol., 11, 49–54.

  • Altieri DC . (2003). Nat. Rev. Cancer, 3, 46–54.

  • Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA and Hamilton TC . (2002). J. Natl. Cancer Inst., 94, 522–528.

  • Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T and Altieri DC . (2003). Clin. Cancer Res., 9, 2683–2692.

  • Edwards E, Geng L, Tan J, Onishko H, Donnelly E and Hallahan DE . (2002). Cancer Res., 62, 4671–4677.

  • Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, Pinedo HM, van Tinteren H and Giaccone G . (2001). Clin. Cancer Res., 7, 2468–2474.

  • Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H and Hallahan DE . (2001). Cancer Res., 61, 2413–2419.

  • Harfouche R, Hassessian HM, Guo Y, Faivre V, Srikant CB, Yancopoulos GD and Hussain SN . (2002). Microvasc. Res., 64, 135–147.

  • Hofmann HS, Simm A, Hammer A, Silber RE and Bartling B . (2002). J. Cancer Res. Clin. Oncol., 128, 554–560.

  • Holcik M, Gibson H and Korneluk RG . (2001). Apoptosis, 6, 253–261.

  • Holcik M, Yeh C, Korneluk RG and Chow T . (2000). Oncogene, 19, 4174–4177.

  • Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD and LaCasse EC . (2003). Clin. Cancer Res., 9, 2826–2836.

  • Ikehara M, Oshita F, Kameda Y, Ito H, Ohgane N, Suzuki R, Saito H, Yamada K, Noda K and Mitsuda A . (2002). Oncol. Rep., 9, 835–838.

  • Jansen B and Zangemeister-Wittke U . (2002). Lancet Oncol., 3, 672–683.

  • Kallio MJ, Nieminen M and Eriksson JE . (2001). FASEB J., 15, 2721–2723.

  • Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M and Hallahan DE . (2004). Cancer Res., 64, 2840–2845.

  • Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC and Altieri DC . (2001). Am. J. Pathol., 158, 1757–1765.

  • Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A and Abad A . (1999). J. Clin. Oncol., 17, 2100–2104.

  • O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS and Altieri DC . (2000). Am. J. Pathol., 156, 393–398.

  • Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U . (2000). Cancer Res., 60, 2805–2809.

  • Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC and Sessa WC . (2000). J. Biol. Chem., 275, 9102–9105.

  • Pennati M, Binda M, Colella G, Folini M, Citti L, Villa R, Daidone MG and Zaffaroni N . (2003). J. Invest. Dermatol., 120, 648–654.

  • Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R and Rodel F . (2003). Int. J. Radiat. Oncol. Biol. Phys., 55, 1341–1347.

  • Salvesen GS and Duckett CS . (2002). Nat. Rev. Mol. Cell. Biol., 3, 401–410.

  • Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau M J, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA and Reed JC . (2004). Cancer Cell, 5, 25–35.

  • Tran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS . (2002). Proc. Natl. Acad. Sci. USA, 99, 4349–4354.

  • Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG and Kerbel RS . (1999). Biochem. Biophys. Res. Commun., 264, 781–788.

  • Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL and Choo KH . (2000). Curr. Biol., 10, 1319–1328.

Download references

Acknowledgements

This work was supported in part by the Vanderbilt Discovery Grant and Vanderbilt Physician Scientist Grant, NIH grants R01-CA58508, R01-CA88076, R01-CA89674 and the Vanderbilt Lung Cancer SPORE, P50-CA90949.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, 1301 22nd Avenue South, B-902 The Vanderbilt Clinic, Nashville, 37232-5671, TN, USA

    Carolyn Cao, Yi Mu, Dennis E Hallahan & Bo Lu

Authors
  1. Carolyn Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dennis E Hallahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bo Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bo Lu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cao, C., Mu, Y., Hallahan, D. et al. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23, 7047–7052 (2004). https://doi.org/10.1038/sj.onc.1207929

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207929

Keywords

This article is cited by

Search

Advanced search

Quick links